ArticleCureus2024
The Efficacy of Eculizumab in the Acute Phase of Neuromyelitis Optica Spectrum Disorder: A Case Series Study.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The Comprehensive Live Cell-Based Cytotoxicity Assay for Monitoring Disease Activity and Guiding Rescue Therapy in Acute Attacks of NMOSD.Annals of clinical and translational neurology · 2026Article
- A novel limited-dose C5 inhibitor add-on as rescue therapy for refractory NMOSD attacks: a practical alternative to conventional multi-dose regimens.BMC neurology · 2026Article
- Granulocyte and astrocyte markers distinguish MOG-antibody disease and neuromyelitis optica from multiple sclerosis.Brain : a journal of neurology · 2026Observational
- Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series.Neurology(R) neuroimmunology & neuroinflammation · 2026Article
- Eculizumab as a rescue therapy in acute-phase aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder.Journal of neurology · 2026Article
- Complement C5 inhibitors as add-on rescue treatment in severe AQP4-antibody neuromyelitis optica spectrum disorder attacks: a case series and literature review.Therapeutic advances in neurological disorders · 2026Article
- Efficacy of Ravulizumab During the Acute Phase of Neuromyelitis Optica Spectrum Disorder.Case reports in neurological medicine · 2026Article
- Complement C5 inhibitor as a rescue therapy for acute NMOSD attacks: a multicenter retrospective cohort study in China.Frontiers in immunology · 2026Article
- Emerging role of complement system in the induction of neuroinflammation in adenylosuccinate lyase deficiency disorder.Brain, behavior, & immunity - health · 2025Review
- Neuromyelitis optica spectrum disorders with recurrent syncope due to area postrema syndrome: a case report and literature review.BMC neurology · 2025Review
- Neuroinflammation: Mechanisms, Dual Roles, and Therapeutic Strategies in Neurological Disorders.Current issues in molecular biology · 2025Review
- Ravulizumab in NMOSD with associated interstitial pneumonitis in a 59-year-old female patient: a case report.Frontiers in immunology · 2025Article
- Eculizumab for the acute attack of neuromyelitis optica spectrum disorder.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eculizumab, a monoclonal antibody against complement C5, has been approved to prevent neuromyelitis optica spectrum disorder (NMOSD) relapse. Although complement activation leads to neuroinflammation and tissue necrosis in NMOSD attacks, clinical reports on the efficacy of eculizumab in the acute phase of NMOSD are limited. To clarify its effectiveness against clinical symptoms in NMOSD attacks, we described five patients with NMOSD who were administered eculizumab soon after treatment for an attack. The patients included four female patients and one male patient aged 50-93 years. The index attacks were optic neuritis in three cases, myelitis in one case, and brainstem encephalitis and myelitis in one case. Three patients had not received any maintenance therapy. Although all patients had received intravenous methylprednisolone (IVMP) and plasma exchange (PE) several times, these treatments were not sufficient to improve their symptoms. Thereafter, eculizumab was initiated between 35 and 61 days after the attack onset and partially ameliorated the symptoms in all cases. These cases suggest eculizumab as a treatment option to lessen the symptoms of severe NMOSD attacks, although the efficacy of IVMP and PE before eculizumab administration cannot be excluded.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.